Limitations and opportunities in the pharmacotherapy of ciliopathies

Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology & therapeutics (Oxford) 2021-09, Vol.225, p.107841-107841, Article 107841
Hauptverfasser: Duong Phu, Max, Bross, Stefan, Burkhalter, Martin D., Philipp, Melanie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 107841
container_issue
container_start_page 107841
container_title Pharmacology & therapeutics (Oxford)
container_volume 225
creator Duong Phu, Max
Bross, Stefan
Burkhalter, Martin D.
Philipp, Melanie
description Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies.
doi_str_mv 10.1016/j.pharmthera.2021.107841
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2506278488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163725821000437</els_id><sourcerecordid>2506278488</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</originalsourceid><addsrcrecordid>eNqFkE1LwzAYgIMobk7_guTopTNp2iY96pwfMPCi4C1k-WAZbVOTVNi_N1unHj298PK8ecgDAMRojhGubrfzfiN8Gzfai3mOcpzWlBX4BEwxo3WWmI9TME2DZDQv2QRchLBFCBUFys_BhBBKccnIFDysbGujiNZ1AYpOQdf3zsehs9HqAG0HkwQebEK6g7DfQWegtI11vYibhF2CMyOaoK-OcwbeH5dvi-ds9fr0srhbZbLIi5gRQ2pM8VpJqgxhqJIGV5WsqdKmVqikUmImJCVpK7RApBakrApaGEoVUoLMwM34bu_d56BD5K0NUjeN6LQbAs9LVOWpA2MJZSMqvQvBa8N7b1vhdxwjvm_It_yvId835GPDdHp9tAzrVqvfw59oCbgfAZ3--mW150Fa3UmtrNcycuXs_5ZvAfWI2A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2506278488</pqid></control><display><type>article</type><title>Limitations and opportunities in the pharmacotherapy of ciliopathies</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Duong Phu, Max ; Bross, Stefan ; Burkhalter, Martin D. ; Philipp, Melanie</creator><creatorcontrib>Duong Phu, Max ; Bross, Stefan ; Burkhalter, Martin D. ; Philipp, Melanie</creatorcontrib><description>Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2021.107841</identifier><identifier>PMID: 33771583</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Autosomal dominant polycystic kidney disease ; Cilia ; Ciliopathies - drug therapy ; Ciliopathy ; Humans ; Primary cilia dyskinesia ; Retinopathies</subject><ispartof>Pharmacology &amp; therapeutics (Oxford), 2021-09, Vol.225, p.107841-107841, Article 107841</ispartof><rights>2021 The Author(s)</rights><rights>Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</citedby><cites>FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pharmthera.2021.107841$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33771583$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Duong Phu, Max</creatorcontrib><creatorcontrib>Bross, Stefan</creatorcontrib><creatorcontrib>Burkhalter, Martin D.</creatorcontrib><creatorcontrib>Philipp, Melanie</creatorcontrib><title>Limitations and opportunities in the pharmacotherapy of ciliopathies</title><title>Pharmacology &amp; therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies.</description><subject>Autosomal dominant polycystic kidney disease</subject><subject>Cilia</subject><subject>Ciliopathies - drug therapy</subject><subject>Ciliopathy</subject><subject>Humans</subject><subject>Primary cilia dyskinesia</subject><subject>Retinopathies</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LwzAYgIMobk7_guTopTNp2iY96pwfMPCi4C1k-WAZbVOTVNi_N1unHj298PK8ecgDAMRojhGubrfzfiN8Gzfai3mOcpzWlBX4BEwxo3WWmI9TME2DZDQv2QRchLBFCBUFys_BhBBKccnIFDysbGujiNZ1AYpOQdf3zsehs9HqAG0HkwQebEK6g7DfQWegtI11vYibhF2CMyOaoK-OcwbeH5dvi-ds9fr0srhbZbLIi5gRQ2pM8VpJqgxhqJIGV5WsqdKmVqikUmImJCVpK7RApBakrApaGEoVUoLMwM34bu_d56BD5K0NUjeN6LQbAs9LVOWpA2MJZSMqvQvBa8N7b1vhdxwjvm_It_yvId835GPDdHp9tAzrVqvfw59oCbgfAZ3--mW150Fa3UmtrNcycuXs_5ZvAfWI2A</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Duong Phu, Max</creator><creator>Bross, Stefan</creator><creator>Burkhalter, Martin D.</creator><creator>Philipp, Melanie</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202109</creationdate><title>Limitations and opportunities in the pharmacotherapy of ciliopathies</title><author>Duong Phu, Max ; Bross, Stefan ; Burkhalter, Martin D. ; Philipp, Melanie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-3f39171bdc7df3806cf166c97def9d057cc18ac73166aea039a356474f77d0da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Autosomal dominant polycystic kidney disease</topic><topic>Cilia</topic><topic>Ciliopathies - drug therapy</topic><topic>Ciliopathy</topic><topic>Humans</topic><topic>Primary cilia dyskinesia</topic><topic>Retinopathies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Duong Phu, Max</creatorcontrib><creatorcontrib>Bross, Stefan</creatorcontrib><creatorcontrib>Burkhalter, Martin D.</creatorcontrib><creatorcontrib>Philipp, Melanie</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Duong Phu, Max</au><au>Bross, Stefan</au><au>Burkhalter, Martin D.</au><au>Philipp, Melanie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limitations and opportunities in the pharmacotherapy of ciliopathies</atitle><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2021-09</date><risdate>2021</risdate><volume>225</volume><spage>107841</spage><epage>107841</epage><pages>107841-107841</pages><artnum>107841</artnum><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>Ciliopathies are a family of rather diverse conditions, which have been grouped based on the finding of altered or dysfunctional cilia, potentially motile, small cellular antennae extending from the surface of postmitotic cells. Cilia-related disorders include embryonically arising conditions such as Joubert, Usher or Kartagener syndrome, but also afflictions with a postnatal or even adult onset phenotype, i.e. autosomal dominant polycystic kidney disease. The majority of ciliopathies are syndromic rather than affecting only a single organ due to cilia being found on almost any cell in the human body. Overall ciliopathies are considered rare diseases. Despite that, pharmacological research and the strive to help these patients has led to enormous therapeutic advances in the last decade. In this review we discuss new treatment options for certain ciliopathies, give an outlook on promising future therapeutic strategies, but also highlight the limitations in the development of therapeutic approaches of ciliopathies.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>33771583</pmid><doi>10.1016/j.pharmthera.2021.107841</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0163-7258
ispartof Pharmacology & therapeutics (Oxford), 2021-09, Vol.225, p.107841-107841, Article 107841
issn 0163-7258
1879-016X
language eng
recordid cdi_proquest_miscellaneous_2506278488
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Autosomal dominant polycystic kidney disease
Cilia
Ciliopathies - drug therapy
Ciliopathy
Humans
Primary cilia dyskinesia
Retinopathies
title Limitations and opportunities in the pharmacotherapy of ciliopathies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A03%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limitations%20and%20opportunities%20in%20the%20pharmacotherapy%20of%20ciliopathies&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Duong%20Phu,%20Max&rft.date=2021-09&rft.volume=225&rft.spage=107841&rft.epage=107841&rft.pages=107841-107841&rft.artnum=107841&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2021.107841&rft_dat=%3Cproquest_cross%3E2506278488%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2506278488&rft_id=info:pmid/33771583&rft_els_id=S0163725821000437&rfr_iscdi=true